Description:attached herewith , Claims:We claim:

1. An anti-PVRIG (Poliovirus Receptor Related lmmunoglobulin Domain Containing Protein) antibody, wherein said anti-PVRIG antibody comprises: the following vhCDR1, vhCDR2, vhCDR3, vlCDR1, vlCDR2 and vlCDR3 sequences or sequences that differ from those CDR amino acid sequences by 1 or 2 amino acid substitutions, wherein vhCDR1, vhCDR2, vhCDR3, vlCDR1, vlCDR2 and vlCDR3 are selected from the group consisting of:
• the vhCDR1 as set out in SEQ ID NO:885, vhCDR2 as set out in SEQ ID NO:886, vhCDR3 as set out in SEQ ID NO:887, vlCDR1 as set out in SEQ ID NO:889, vlCDR2 as set out in SEQ ID NO:890 and vlCDR3 as set out in SEQ ID NO:891; and
• the vhCDR1 as set out in SEQ ID NO:981, vhCDR2 as set out in SEQ ID NO:982, vhCDR3 as set out in SEQ ID NO:983, vlCDR1 as set out in SEQ ID NO:985, vlCDR2 as set out in SEQ ID NO:986 and vlCDR3 as set out in SEQ ID NO:987.

2. The anti-PVRIG antibody as claimed in claim 1, wherein the anti-PVRIG antibody comprises:
(i) a heavy chain variable domain at least 90% identical to SEQ ID NO:1434 and
(ii) a light chain variable domain at least 90% identical to SEQ ID NO:1453.

3. The anti-PVRIG antibody as claimed in claim 1 or claim 2, wherein the anti-PVRIG antibody comprises:
(i) a heavy chain variable domain at least 95% identical to SEQ ID NO:1434 and
(ii) a light chain variable domain at least 95% identical to SEQ ID NO:1453.

4. The anti-PVRIG antibody as claimed in claim 1, wherein the anti-PVRIG antibody comprises:
(i) a heavy chain variable domain at least 90% identical to SEQ ID NO:1447 and
(ii) a light chain variable domain at least 90% identical to SEQ ID NO:1462.

5. The anti-PVRIG antibody as claimed in any one of claims 1 to 4, wherein the anti-PVRIG antibody comprises:
(i) a heavy chain variable domain at least 95% identical to SEQ ID NO:1447 and
(ii) a light chain variable domain at least 95% identical to SEQ ID NO:1462.

6. An anti-PVRIG antibody competing with an antibody as claimed in any one of claims 1 to 5 to specifically bind to the PVRIG molecule.

7. The anti-PVRIG antibody as claimed in any one of claims 1 to 6 for use in the treatment of cancer, wherein the antibody activates T cells and/or NK cells.

8. The anti-PVRIG antibody for use in the treatment of cancer as claimed in claim 7, wherein the anti-PVRIG antibody is used in combination with antibodies targeting additional immune checkpoints.

9. The anti-PVRIG antibody for use in the treatment of cancer as claimed in claim 8, wherein the antagonistic antibodies targeting additional immune checkpoints include anti-TIGIT antibodies, anti-CTLA-4 antibodies, anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-LAG-3 antibodies, anti-TIM-3 antibodies, anti-BTLA antibodies, anti-B7-H4 antibodies, anti-B7-H3 antibodies and anti-VISTA antibodies.

10. The anti-PVRIG antibody for use in the treatment of cancer as claimed in claim 9, wherein anti-CTLA4 antibodies include ipilimumab and tremelimumab.

11. The anti-PVRIG antibody for use in the treatment of cancer as claimed in claim 9, wherein anti-PD-1 antibodies include nivolumab BMS-936558/MDX-1106/ONO-4538, AMP224, CT-011 and MK-3475.

12. The anti-PVRIG antibody for use in the treatment of cancer as claimed in claim 9, wherein anti-PDL-1 antibodies include BMS-936559/MDX-1105, MEDl4736 and RG-7446/ MPDL3280A.

13. The anti-PVRIG antibody for use in the treatment of cancer as claimed in claim 9, wherein anti-LAG-3 antibodies include IMP-321.

14. The anti-PVRIG antibody for use in the treatment of cancer as claimed in claim 7, wherein the anti-PVRIG antibody is used in combination with an anti-TIGIT antibody.

15. Use of an anti-PVRIG antibody in the manufacture of a medicament for activating T-cells of a patient with cancer, wherein the anti-PVRIG antibody comprises:
a) the vhCDRl, vhCDR2, and vhCDR3 from SEQ ID NO:1434 and
b) the vlCDRl, vlCDR2, and vlCDR3 from SEQ ID NO:1453,
wherein said CDRs comprise from 1 to 6 substitutions and wherein no individual CDR comprises more than 1 substitution, and
wherein a subset of said T-cells of said patient are activated.

16. Use of an anti-PVRIG antibody in the manufacture of a medicament for activating T-cells of a patient with cancer, wherein the anti-PVRIG antibody comprises:
i) a heavy chain variable domain comprising the vhCDR1, vhCDR2, and vhCDR3 from SEQ ID NO:1434 and wherein said heavy chain variable domain comprises a sequence exhibiting at least 90% identity to SEQ ID NO:1434, wherein each individual vhCDR from SEQ ID NO:1434 comprises no more than 1 substitution, and
ii) a light chain variable domain comprising the vlCDR1, vlCDR2, and vlCDR3 from SEQ ID NO:1453 and wherein said light chain variable domain comprises a sequence exhibiting at least 90% identity to SEQ ID NO:1453, wherein each individual vlCDR from SEQ ID NO:1453 comprises no more than 1 substitution, and
wherein a subset of said T-cells of said patient are activated.

17. Use of an anti-PVRIG antibody in the manufacture of a medicament for activating T-cells and/or NK cells of a patient with cancer, wherein said anti-PVRIG antibody comprises:
i) a heavy chain variable domain comprising the vhCDR1, vhCDR2, and vhCDR3 from SEQ ID NO:1434 and wherein said heavy chain variable domain comprises a sequence exhibiting at least 90% identity to SEQ ID NO:1434, wherein each individual vhCDR from SEQ ID NO:1434 comprises no more than 1 substitution, and
ii) a light chain variable domain comprising the vlCDR1, vlCDR2, and vlCDR3 from SEQ ID NO:1453 and wherein said light chain variable domain comprises a sequence exhibiting at least 90% identity to SEQ ID NO:1453, wherein each individual vlCDR from SEQ ID NO:1453 comprises no more than 1 substitution, and
wherein a subset of said T-cells and/or NK cells of said patient are activated.

18. Use of an anti-PVRIG antibody in the manufacture of a medicament for activating T-cells and/or NK cells of a patient with cancer, wherein said anti-PVRIG antibody comprises:
a) the vhCDRl, vhCDR2, and vhCDR3 from SEQ ID NO:1447 and
b) the vlCDRl, vlCDR2, and vlCDR3 from SEQ ID NO:1462,
wherein said CDRs comprise from 1 to 6 substitutions, and no said CDR comprises more than 1 substitution, and
wherein a subset of said T-cells and/or NK cells of said patient are activated.

19. Use of an anti-PVRIG antibody in the manufacture of a medicament for activating T-cells and/or NK cells of a patient with cancer, wherein said anti-PVRIG antibody comprises:
i) a heavy chain variable domain comprising a sequence exhibiting at least 90% identity to SEQ ID NO:1447, wherein each individual vhCDR from SEQ ID NO:1447 comprises no more than 1 substitution, and
ii) a light chain variable domain comprising a sequence exhibiting at least 90% identity to SEQ ID NO:1462, wherein each individual vlCDR from SEQ ID NO:1462 comprises no more than 1 substitution, and
wherein a subset of said T-cells and/or NK cells of said patient are activated.

20. Use of an anti-PVRIG antibody in the manufacture of a medicament for activating T-cells and/or NK cells of a patient with cancer, wherein said anti-PVRIG antibody comprises:
i) a heavy chain variable domain comprising the vhCDR1, vhCDR2, and vhCDR3 from SEQ ID NO:1447 and wherein said heavy chain variable domain comprises a sequence exhibiting at least 90% identity to SEQ ID NO:1447, and
ii) a light chain variable domain comprising the vlCDR1, vlCDR2, and vlCDR3 from SEQ ID NO:1462 and wherein said light chain variable domain comprises a sequence exhibiting at least 90% identity to SEQ ID NO:1462, and
wherein a subset of said T-cells and/or NK cells of said patient are activated.

21. Use of an anti-PVRIG antibody in the manufacture of a medicament for activating T-cells and/or NK cells of a patient with cancer, wherein said anti-PVRIG antibody comprises:
a) a heavy chain variable domain comprising:
i) a vhCDR1 selected from the group consisting of SEQ ID NO:885 or a SEQ ID NO:885 variant comprising 1 amino acid substitution;
ii) a vhCDR2 selected from the group consisting of SEQ ID NO:886 or a SEQ ID NO:886 variant comprising 1 amino acid substitution;
iii) a vhCDR3 selected from the group consisting of SEQ ID NO:887 or a SEQ ID NO:887 variant comprising 1 amino acid substitution; and
b) a light chain variable domain comprising:
i) a vlCDR1 selected from the group consisting of SEQ ID NO:889 or a SEQ ID NO:889 variant comprising 1 amino acid substitution;
ii) a vlCDR2 selected from the group consisting of SEQ ID NO:890 or a SEQ ID NO:890 variant comprising 1 amino acid substitution;
iii) a vlCDR3 selected from the group consisting of SEQ ID NO:891 or a SEQ ID NO:891 variant comprising 1 amino acid substitution, and
wherein said CDRs comprise from 1 to 6 amino acid substitutions, and wherein a subset of said T-cells of said patient are activated.

22. Use of an anti-PVRIG antibody in the manufacture of a medicament for activating T-cells and/or NK cells of a patient with cancer, wherein said anti-PVRIG antibody comprises:
i) a heavy chain variable domain comprising the vhCDRl, vhCDR2, and vhCDR3 from SEQ ID NO:1434 and
ii) a light chain variable domain comprising the vlCDRl, vlCDR2, and vlCDR3 from SEQ ID NO:1453,
wherein a subset of said T-cells and/or NK cells of said patient are activated; and wherein said anti-PVRIG antibody is formulated for administration with an anti-PD-L1 antibody.

23. The use as claimed in claim 22, wherein said anti-PVRIG antibody comprises the heavy chain variable domain of SEQ ID NO:1434 and the light chain variable domain of SEQ ID NO:1453.

24. Use of an anti-PVRIG antibody in the manufacture of a medicament for activating T-cells and/or NK cells of a patient with cancer, wherein said anti-PVRIG antibody comprises:
i) a heavy chain variable domain comprising the vhCDRl, vhCDR2, and vhCDR3 from SEQ ID NO:1447 and
ii) a light chain variable domain comprising the vlCDRl, vlCDR2, and vlCDR3 from SEQ ID NO:1462,
wherein a subset of said T-cells and/or NK cells of said patient are activated; and wherein said anti-PVRIG antibody is formulated for administration with an anti-PD-L1 antibody.

25. The use as claimed in claim 24, wherein said anti-PVRIG antibody comprises the heavy chain variable domain of SEQ ID NO:1447 and the light chain variable domain of SEQ ID NO:1462.

26. Use of an anti-PVRIG antibody in the manufacture of a medicament for activating T-cells and/or NK cells of a patient with cancer, wherein said anti-PVRIG antibody comprises:
a) a heavy chain variable domain comprising:
i) a vhCDRl comprising SEQ ID NO:885;
ii) a vhCDR2 comprising SEQ ID NO:886;
iii) a vhCDR3 comprising SEQ ID NO:887; and
b) a light chain variable domain comprising:
i) a vlCDRl comprising SEQ ID NO:889;
ii) a vlCDR2 comprising SEQ ID NO:890;
iii) a vlCDR3 comprising SEQ ID NO:891,
wherein a subset of said T-cells and/or NK cells of said patient are activated; and wherein said anti-PVRIG antibody is formulated for administration with an anti-PD-L1 antibody.

27. The use as claimed in any one of claims 15-26, wherein said anti-PVRIG antibody comprises the CH1-hinge-CH2-CH3 region from IgGl, IgG2, IgG3, or IgG4, wherein said hinge region optionally comprises mutations.

28. Use of an anti-PVRIG antibody in the manufacture of a medicament for activating T-cells and/or NK cells of a patient with cancer, wherein said anti-PVRIG antibody comprises:
a) a heavy chain comprising:
i) a VH-CH1-hinge-CH2-CH3, wherein the VH is SEQ ID NO:1434 and wherein the CH1-hinge-CH2-CH3 region is from IgG4; and
b) a light chain comprising:
i) a VL-CL, wherein the VL is SEQ ID NO:1453 and wherein the CL region is from human kappa 2 light chain;
and wherein said anti-PVRIG antibody is formulated for administration with an anti-PD-L1 antibody.

29. Use of an anti-PVRIG antibody in the manufacture of a medicament for activating T-cells and/or NK cells of a patient with cancer, wherein said anti-PVRIG antibody comprises:
a) a heavy chain comprising:
i) a VH-CH1-hinge-CH2-CH3, wherein the VH is SEQ ID NO:1447 and wherein the CH1-hinge-CH2-CH3 region is from IgG4; and
b) a light chain comprising:
i) a VL-CL, wherein the VL is SEQ ID NO:1462 and wherein the CL region is from human kappa 2 light chain;
and wherein said anti-PVRIG antibody is formulated for administration with an anti-PD-L1 antibody.

30. The use as claimed in claim 28 or claim 29, wherein said hinge region optionally comprises mutations.

31. Use of an anti-PVRIG antibody in the manufacture of a medicament for activating T-cells and/or NK cells of a patient with cancer, wherein said anti-PVRIG antibody comprises:
i) a heavy chain variable domain comprising the vhCDR1, vhCDR2, and vhCDR3 from SEQ ID NO:1434 and
ii) a light chain variable domain comprising the vlCDR1, vlCDR2, and vlCDR3 from SEQ ID NO:1453,
wherein a subset of said T-cells and/or NK cells of said patient are activated and wherein said anti-PVRIG antibody is formulated for administration with an anti-PD-1 protein.
32. The use as claimed in claim 31 wherein said anti-PVRIG antibody comprises the heavy chain variable domain of SEQ ID NO:1434 and the light chain variable domain of SEQ ID NO:1453.

33. Use of an anti-PVRIG antibody in the manufacture of a medicament for activating T-cells and/or NK cells of a patient with cancer, wherein said anti-PVRIG antibody comprises:
i) a heavy chain variable domain comprising the vhCDR1, vhCDR2, and vhCDR3 from SEQ ID NO:1447 and
ii) a light chain variable domain comprising the vlCDR1, vlCDR2, and vlCDR3 from SEQ ID NO:1462,
wherein a subset of said T-cells and/or NK cells of said patient are activated and wherein said anti-PVRIG antibody is formulated for administration with an anti-PD-1 protein.

34. The use as claimed in claim 33 wherein said antibody comprises the heavy chain variable domain of SEQ ID NO:1447 and the light chain variable domain of SEQ ID NO:1462.

35. Use of an anti-PVRIG antibody in the manufacture of a medicament for activating T-cells and/or NK cells of a patient with cancer, wherein said anti-PVRIG antibody comprises:
a) a heavy chain variable domain comprising:
i) a vhCDR1 comprising SEQ ID NO:885;
ii) a vhCDR2 comprising SEQ ID NO:886;
iii) a vhCDR3 comprising SEQ ID NO:887; and
b) a light chain variable domain comprising:
i) a vlCDR1 comprising SEQ ID NO:889;
ii) a vlCDR2 comprising SEQ ID NO:890;
iii) a vlCDR3 comprising SEQ ID NO:891,
wherein a subset of said T-cells and/or NK cells of said patient are activated and wherein said anti-PVRIG antibody is formulated for administration with an anti-PD-1 protein.

36. The use as claimed in any one of claims 33-35 wherein said anti-PVRIG antibody comprises the CH1-hinge-CH2-CH3 region from IgG1, IgG2, IgG3, or IgG4, wherein said hinge region optionally comprises mutations.

37. Use of an anti-PVRIG antibody in the manufacture of a medicament for activating T-cells and/or NK cells of a patient with cancer, wherein said anti-PVRIG antibody comprises:
a) a heavy chain comprising:
i) a VH-CH1-hinge-CH2-CH3, wherein the VH is SEQ ID NO:1434 and wherein the CH1-hinge-CH2-CH3 region is from IgG4; and
b) a light chain comprising:
i) a VL-CL, wherein the VL is SEQ ID NO:1453 and wherein the CL region is from human kappa 2 light chain
and wherein said anti-PVRIG antibody is formulated for administration with an anti-PD-1 protein.

38. Use of an anti-PVRIG antibody in the manufacture of a medicament for activating T-cells and/or NK cells of a patient with cancer, wherein said anti-PVRIG antibody comprises:
a) a heavy chain comprising:
i) a VH-CH1-hinge-CH2-CH3, wherein the VH is SEQ ID NO:1447 and wherein the CH1-hinge-CH2-CH3 region is from IgG4; and
b) a light chain comprising:
i) a VL-CL, wherein the VL is SEQ ID NO:1462 and wherein the CL region is from human kappa 2 light chain
and wherein said anti-PVRIG antibody is formulated for administration with an anti-PD-1 protein.

39. The use as claimed in claim 37 or claim 38 wherein said hinge region optionally comprises mutations.

40. The use as claimed in any one of claims 31-39 wherein said anti-PD-1 protein is an anti-PD-1 antibody.
41. The use as claimed in claim 40 wherein said anti-PD-1 antibody is Keytruda® (pembrolizumab).

42. The use as claimed in claim 40 wherein said anti-PD-1 antibody is Opdivo® (nivolumab).

43. Use of an anti-PVRIG antibody in the manufacture of a medicament for activating T-cells and/or NK cells of a patient with cancer, wherein said anti-PVRIG antibody comprises:
i) a heavy chain variable domain comprising the vhCDRl, vhCDR2, and vhCDR3 from SEQ ID NO:1434 and
ii) a light chain variable domain comprising the vlCDRl, vlCDR2, and vlCDR3 from SEQ ID NO:1453,
wherein a subset of said T-cells and/or NK cells of said patient are activated
and wherein said anti-PVRIG antibody is formulated for administration with an anti-TIGIT antibody.

44. The use as claimed in claim 43, wherein said anti-PVRIG antibody comprises the heavy chain variable domain of SEQ ID NO:1434 and the light chain variable domain of SEQ ID NO:1453.

45. Use of an anti-PVRIG antibody in the manufacture of a medicament for activating T-cells and/or NK cells of a patient with cancer, wherein said anti-PVRIG antibody comprises:
i) a heavy chain variable domain comprising the vhCDRl, vhCDR2, and vhCDR3 from SEQ ID NO:1447 and
ii) a light chain variable domain comprising the vlCDRl, vlCDR2, and vlCDR3 from SEQ ID NO:1462,
wherein a subset of said T-cells and/or NK cells of said patient are activated
and wherein said anti-PVRIG antibody is formulated for administration with an anti-TIGIT antibody.

46. The use as claimed in claim 45, wherein said anti-PVRIG antibody comprises the heavy chain variable domain of SEQ ID NO:1447 and the light chain variable domain of SEQ ID NO:1462.

47. Use of an anti-PVRIG antibody in the manufacture of a medicament for activating T-cells and/or NK cells of a patient with cancer, wherein said anti-PVRIG antibody comprises:
a) a heavy chain variable domain comprising:
i) a vhCDRl comprising SEQ ID NO:885;
ii) a vhCDR2 comprising SEQ ID NO:886;
iii) a vhCDR3 comprising SEQ ID NO:887; and
b) a light chain variable domain comprising:
i) a vlCDRl comprising SEQ ID NO:889;
ii) a vlCDR2 comprising SEQ ID NO:890;
iii) a vlCDR3 comprising SEQ ID NO:891,
wherein a subset of said T-cells and/or NK cells of said patient are activated
and wherein said anti-PVRIG antibody is formulated for administration with an anti-TIGIT antibody.

48. The use as claimed in any one of claims 43-47, wherein said anti-PVRIG antibody comprises the CH1-hinge-CH2-CH3 region from IgGl, IgG2, IgG3, or IgG4, wherein said hinge region optionally comprises mutations.

49. The use as claimed in any one of claims 43-47, wherein said anti-PVRIG antibody comprises the CL region of human kappa 2 light chain.

50. The use as claimed in any one of claims 43-47, wherein said T-cells are cytotoxic T-cells (CTLs).

51. The use as claimed in any one of claims 43-47, wherein said T-cells are selected from the group consisting of CD4+ T-cells and CD8+ T-cells.

52. The use as claimed in any one of claims 43-47, wherein said activation is measured as an increase in interferon-y production and/or an increase in cytokine secretion.

53. Use of an anti-PVRIG antibody in the manufacture of a medicament for activating T-cells and/or NK cells of a patient with cancer, wherein said anti-PVRIG antibody comprises:
a) a heavy chain comprising:
i) a VH-CH1-hinge-CH2-CH3, wherein the VH is SEQ ID NO:1434 and wherein the CH1-hinge-CH2-CH3 region is from IgG4; and
b) a light chain comprising:
i) a VL-CL, wherein the VL is SEQ ID NO:1453 and wherein the CL region is from human kappa 2 light chain
and wherein said anti-PVRIG antibody is formulated for administration with an anti-TIGIT antibody.

54. Use of an anti-PVRIG antibody in the manufacture of a medicament for activating T-cells and/or NK cells of a patient with cancer, wherein said anti-PVRIG antibody comprises:
a) a heavy chain comprising:
i) a VH-CH1-hinge-CH2-CH3, wherein the VH is SEQ ID NO:1447 and wherein the CH1-hinge-CH2-CH3 region is from IgG4; and
b) a light chain comprising:
i) a VL-CL, wherein the VL is SEQ ID NO:1462 and wherein the CL region is from human kappa 2 light chain
and wherein said anti-PVRIG antibody is formulated for administration with an anti-TIGIT antibody.

55. The use as claimed in claim 53 or claim 54, wherein said hinge region optionally comprises mutations.

56. An anti-PVRIG antibody comprising:
i) a heavy chain variable domain of SEQ ID NO:1434 and
ii) a light chain variable domain of SEQ ID NO:1453,
wherein said anti-PVRIG antibody comprises: the vhCDR1 (SEQ ID NO:885), vhCDR2 (SEQ ID NO:886), vhCDR3 (SEQ ID NO:887), vlCDR1 (SEQ ID NO:889), vlCDR2 (SEQ ID NO:890) and vlCDR3 (SEQ ID NO:891).

57. A nucleic acid composition comprising:
a) a first nucleic acid encoding the heavy chain variable domain of SEQ ID NO:1434; and
b) a second nucleic acid encoding the light chain variable domain of SEQ ID NO:1453
wherein said anti-PVRIG antibody comprises: the vhCDR1 (SEQ ID NO:885), vhCDR2 (SEQ ID NO:886), vhCDR3 (SEQ ID NO:887), vlCDR1 (SEQ ID NO:889), vlCDR2 (SEQ ID NO:890) and vlCDR3 (SEQ ID NO:891).

58. An expression vector composition comprising:
a) a first expression vector comprising said first nucleic acid as claimed in claim 57; and
b) a second expression vector comprising said second nucleic acid as claimed in claim 57.

59. An expression vector composition comprising an expression vector comprising said first nucleic acid as claimed in claim 57 and said second nucleic acid as claimed in claim 57.

60. A host cell comprising the expression vector composition as claimed in claim 58 or 59.

61. A method of making an anti-PVRIG antibody comprising:
a) culturing the host cell as claimed in claim 60 under conditions wherein said antibody is expressed; and
b) recovering said antibody.

62. An anti-PVRIG antibody comprising
i) a heavy chain variable domain of SEQ ID NO:1447 and
ii) a light chain variable domain of SEQ ID NO:1462,
wherein said anti-PVRIG antibody comprises: the vhCDR1 (SEQ ID NO:981), vhCDR2 (SEQ ID NO:982), vhCDR3 (SEQ ID NO:983), vlCDR1 (SEQ ID NO:985), vlCDR2 (SEQ ID NO:986) and vlCDR3 (SEQ ID NO:987) sequences.

63. A nucleic acid composition comprising:
a) a first nucleic acid encoding the heavy chain variable domain of SEQ ID NO:1447; and
b) a second nucleic acid encoding the light chain variable domain of SEQ ID NO:1462,
wherein said anti-PVRIG antibody comprises: the vhCDR1 (SEQ ID NO:981), vhCDR2 (SEQ ID NO:982), vhCDR3 (SEQ ID NO:983), vlCDR1 (SEQ ID NO:985), vlCDR2 (SEQ ID NO:986) and vlCDR3 (SEQ ID NO:987) sequences.

64. An expression vector composition comprising:
a) a first expression vector comprising said first nucleic acid as claimed in claim 63; and
b) a second expression vector comprising said second nucleic acid as claimed in claim 63.

65. An expression vector composition comprising an expression vector comprising said first nucleic acid as claimed in claim 63 and said second nucleic acid as claimed in claim 63.

66. A host cell comprising the expression vector composition as claimed in claim 64 or 65.

67. A method of making an anti-PVRIG antibody comprising:
a) culturing the host cell as claimed in claim 66 under conditions wherein said antibody is expressed; and
b) recovering said antibody.

68. The pharmaceutical composition comprising an anti-PVRIG antibody as claimed in claim 56 or 62 wherein the composition is for the treatment of cancer.